NSTC First Friday Bioscience - Developing New Drug Therapies in Today's Financial & Regulatory Environment - Can the Risks be Justified?

Friday, June 6 2014
12:30 pm – 2:00 pm

Location: McLane Law Firm, 300 TradeCenter, Woburn, MA


Dr. Pravin Chaturvedi, CEO and Founder or Boston-based IndUS Pharmaceuticals, will provide an overview of the risks of drug discovery and development for new molecular entities (NMEs) and challenges in financing such ventures – as well as the rationale that building therapeutic biotech ventures is primarily for patient benefit and long-term value creation.



Dr. Pravin Chaturvedi is CEO and founder of Boston-based IndUS Pharmaceuticals and a co-founder of Florida-based Oceanyx Pharmaceuticals. He also serves as the Chief Scientific Officer of San Francisco-based Napo Pharmaceuticals. Previously, Dr. Pravin served as President and CEO of Scion Pharmaceuticals, and he remains or has served on the boards of IndUS, Oceanyx, FuelEd Schools, Cellanyx, Sindu Scion and TiE Boston.  Over his 25-year career, Dr. Chaturvedi has participated or led the discovery and/or development activities for multiple new chemical entities (NCEs), culminating in the successful development and commercialization of seven new drugs that are currently marketed by various companies.  Dr. Chaturvedi  also spent several years at Vertex Pharmaceuticals as the Head of Lead Evaluation and was in the preclinical group at Alkermes. He began his R&D career at Parke-Davis/Warner-Lambert Company (now Pfizer).  Dr. Chaturvedi holds a Ph.D. in Pharmaceutical Sciences from West Virginia University and a Bachelor’s in Pharmacy from the University of Bombay. 

Refreshments served:

Pizza, salads, and soft drinks


Founded in 2001, Frontage is a global, integrated contract research organization (CRO) serving clients within pharma and biotech companies.  With headquarters in Exton, Pennsylvania, and a division in Shanghai, China, the company offers drug R&D services that combine unmatched quality, speed, and value. Frontage’s expertise in preclinical, CMC, bioanalytical, biologics, and clinical services is fully integrated so programs run smoothly from inception to regulatory submission.

Share MassBio